Clinical Trials Logo

Disruptive Behavior Disorder clinical trials

View clinical trials related to Disruptive Behavior Disorder.

Filter by:

NCT ID: NCT01750996 Completed - Clinical trials for Disruptive Behavior Disorder

Strongest Families Finland Canada: Family-based Prevention and Treatment Program of Early Childhood Disruptive Behavior

Fin-Can
Start date: October 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of the Strongest Families Finland Canada project is to help parents develop skills to strengthen their families and reduce disruptive behavior in their 4 year old children.

NCT ID: NCT00266552 Completed - Conduct Disorder Clinical Trials

A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the effectiveness and safety of an oral solution of risperidone (an antipsychotic medication) versus placebo in the treatment of conduct disorder in children with mild, moderate, or borderline mental retardation.

NCT ID: NCT00250354 Completed - Conduct Disorder Clinical Trials

A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation

Start date: September 1997
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the safety and effectiveness of oral risperidone (an antipsychotic medication) in the treatment of conduct disorder and other disruptive behavior disorders in children ages 5 to 12 with mild, moderate, or borderline mental retardation.

NCT ID: NCT00236470 Completed - Clinical trials for Disruptive Behavior Disorder

A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders

Start date: January 2002
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to document the long-term safety of an oral formulation of risperidone in the treatment of children and adolescents with conduct and other disruptive behavior disorders. Data on the efficacy of the drug will also be collected. Only patients who were enrolled in the previous related study would be eligible to participate.